Top Authors

• Most frequent coverage on SLXP

• 
  Mike Havrilla (1956 followers)

  • FDA Calendar Extreme Trades: 85 Single Digit Stocks (Wed, Oct 14)
  • Pending FDA Decisions: 20 Extreme Trades (Mon, Jun 22)
  • FDA, Clinical Trial Updates: Biogen, Roche, Salix, Cell Therapeutics, Pfizer (Wed, May 20)

  More by Mike Havrilla on SLXP »
• 
  Justin M. Hall (672 followers)

  • Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers (Sun, Sep 20)
  • Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up (Fri, Sep 11)

  More by Justin M. Hall on SLXP »
• 
  SA Editor Eli Hoffmann (1053 followers)

  • Ten Must-Know Stories for Monday (Mon, Dec 31)

  More by SA Editor Eli Hoffmann on SLXP »

• Most followed authors on SLXP

• 
  Mike Havrilla (1956 followers)

  • FDA Calendar Extreme Trades: 85 Single Digit Stocks (Wed, Oct 14)
  • Pending FDA Decisions: 20 Extreme Trades (Mon, Jun 22)
  • FDA, Clinical Trial Updates: Biogen, Roche, Salix, Cell Therapeutics, Pfizer (Wed, May 20)

  More by Mike Havrilla on SLXP »
• 
  Andrew Wilkinson (1174 followers)

  • Monday Options Update: AMAG, XME, THOR, MSFT, SLXP, CEG, ING, RIMM (Mon, Oct 20)

  More by Andrew Wilkinson on SLXP »
• 
  Zacks.com (1084 followers)

  • Salix: Approval of Rifaximin Would Help Drive Long-Term Growth (Tue, Sep 29)

  More by Zacks.com on SLXP »

• Newest authors on SLXP

• 
  Justin M. Hall (672 followers)

  • Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers (Sun, Sep 20)
  • Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up (Fri, Sep 11)

  More by Justin M. Hall on SLXP »
• 
  M. E. Garza (549 followers)

  • Salix Pharma Continues to Rise in Anticipation of FDA Decision (Sun, Sep 6)

  More by M. E. Garza on SLXP »
• 
  Midnight Trader (188 followers)

  • Closing Update: Stocks Manage Narrowly Higher Finish (Mon, Sep 14)

  More by Midnight Trader on SLXP »

• Most commented on SLXP

• 
  Justin M. Hall (672 followers)

  • Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers (Sun, Sep 20)
  • Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up (Fri, Sep 11)

  More by Justin M. Hall on SLXP »
• 
  Mike Havrilla (1956 followers)

  • FDA Calendar Extreme Trades: 85 Single Digit Stocks (Wed, Oct 14)
  • Pending FDA Decisions: 20 Extreme Trades (Mon, Jun 22)
  • FDA, Clinical Trial Updates: Biogen, Roche, Salix, Cell Therapeutics, Pfizer (Wed, May 20)

  More by Mike Havrilla on SLXP »
• 
  Midnight Trader (188 followers)

  • Closing Update: Stocks Manage Narrowly Higher Finish (Mon, Sep 14)

  More by Midnight Trader on SLXP »